LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

Kodu・Aktsiate loetelu・Cytek Biosciences Inc

Cytek Biosciences Inc

Suletud

SektorTervishoid

3.76 5.32

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.49

Max

3.83

Põhinäitajad
By Trading Economics
Sissetulek	25M -19M
Müük	-18M 44M
Aktsiakasum	-0.096
Kasumimarginaal	-42.746
Töötajad	678
EBITDA	-15M -16M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+50.42% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-143M 458M
Eelmine avamishind	-1.56
Eelmine sulgemishind	3.76

Uudiste sentiment

By Acuity

50%

159 / 345 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

3.7 / 3.8 Toetus ja vastupanu

Cytek Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

20. mai 2026, 23:31 UTC

Kuumad aktsiad

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20. mai 2026, 22:52 UTC

Suurimad hinnamuutused turgudel

Osisko Shares Fall on Planned Convertible Notes Offering

20. mai 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20. mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20. mai 2026, 23:44 UTC

Tulu

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20. mai 2026, 23:35 UTC

Market Talk

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20. mai 2026, 23:30 UTC

Market Talk

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20. mai 2026, 23:17 UTC

Market Talk

Global Equities Roundup: Market Talk

20. mai 2026, 23:17 UTC

Market Talk

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20. mai 2026, 23:15 UTC

Market Talk

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20. mai 2026, 23:14 UTC

Tulu

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20. mai 2026, 23:02 UTC

Market Talk

KMD Brands Faces Two Testing Hurdles -- Market Talk

20. mai 2026, 22:57 UTC

Market Talk

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20. mai 2026, 22:57 UTC

Market Talk

Global Energy Roundup: Market Talk

20. mai 2026, 22:57 UTC

Market Talk

Global Equities Roundup: Market Talk

20. mai 2026, 22:51 UTC

Market Talk

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20. mai 2026, 22:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20. mai 2026, 22:27 UTC

Market Talk

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20. mai 2026, 22:14 UTC

Market Talk

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20. mai 2026, 22:10 UTC

Tulu

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20. mai 2026, 22:00 UTC

Tulu

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20. mai 2026, 21:38 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20. mai 2026, 21:27 UTC

Tulu

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20. mai 2026, 21:20 UTC

Tulu

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20. mai 2026, 21:19 UTC

Tulu

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20. mai 2026, 21:18 UTC

Tulu

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20. mai 2026, 21:17 UTC

Tulu

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20. mai 2026, 21:17 UTC

Tulu

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20. mai 2026, 21:17 UTC

Tulu

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20. mai 2026, 21:16 UTC

Tulu

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Cytek Biosciences Inc Prognoos

Hinnasiht

By TipRanks

50.42% tõus

12 kuu keskmine prognoos

Keskmine 5.34 USD 50.42%

Kõrge 7.5 USD

Madal 4.12 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Cytek Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Cytek Biosciences Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

3.7 / 3.8Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

159 / 345 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.